UNSPSC 51181928: Cyclofenil diphenol

This classification denotes an antiestrogen with the molecular formula C19H20O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 00W4083OML, chemically known as .alpha.-cyclohexylidene-.alpha.-(p-hydroxyphenyl)-p-cresol, but more generally known as cyclofenil diphenol, which bears US NIH Compound Identifier 21260. European Medicines Agency schedules cyclofenil diphenol or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06852MIG.

Most nations, for tariff purposes, schedule cyclofenil diphenol under HS 29153980. SMILES: C1CC(CCC1C(=C2CCCCC2)C3CCC(CC3)O)O.

UNSPSC 51181928 Cyclofenil diphenol is a Commodity code representing pharmaceutical active ingredients and finished-dose products procured by state and local health systems, corrections facilities, and public-health agencies. Recent state and local activity under this code centers on generic multi-source pharmaceuticals and over-the-counter products supplied through cooperative purchasing agreements, where vendors contract to provide pharmaceutical inventory across multiple participating jurisdictions at negotiated pricing. The work involves manufacturing compliance certification, supply-chain security documentation, wholesaler-relationship management, and tiered pricing structures (flat price, net-price formats, or WAC-minus arrangements) rather than drug development or clinical research.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 for multiple contracts covering generic pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon; proposals are due March 26, 2026. MMCAP contracts require vendors to maintain active relationships with three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify cGMP and Drug Supply Chain Security Act compliance, carry comprehensive liability insurance ($5 million general liability, $2 million network security and privacy, $2 million professional liability), and accept a 3 percent administrative fee. Evaluation weights price competitiveness at 75 percent, with smaller components for administrative-format compliance (5 percent), EDI capability (5 percent), fixed pricing (10 percent), and the 3 percent fee agreement (5 percent). Award contracts are effective July 1, 2026 for a two-year initial term with optional extensions at MMCAP's discretion; the solicitation does not disclose budget ranges or specific set-aside restrictions.